Literature DB >> 23999711

Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.

Ali Sayadmanesh1, Firouz Ebrahimi1, Abbas Hajizade1, Mosayeb Rostamian1, Hani Keshavarz1.   

Abstract

BACKGROUND: Botulinum neurotoxin (BoNT) complexes consist of neurotoxin and neurotoxin-associated proteins. Hemagglutinin-33 (HA-33) is a member of BoNT type A (BoNT/A) complex. Considering the protective role of HA-33 in preservation of BoNT/A in gastrointestinal harsh conditions and also its adjuvant role, recombinant production of this protein is favorable. Thus in this study, HA-33 was expressed and purified, and subsequently its antigenicity in mice was studied.
METHODS: Initially, ha-33 gene sequence of Clostridium botulinum serotype A was adopted from GenBank. The gene sequence was optimized and synthesized in pET28a (+) vector. E. coli BL21 (DE3) strain was transformed by the recombinant vector and the expression of HA-33 was optimized at 37°C and 5 h induction time.
RESULTS: The recombinant protein was purified by nickel nitrilotriacetic acid agarose affinity chromatography and confirmed by immunoblotting. Enzyme Linked Immunoassay showed a high titer antibody production in mice.
CONCLUSION: The results indicated a highly expressed and purified recombinant protein, which is able to evoke high antibody titers in mice.

Entities:  

Keywords:  Botulinum neurotoxin; Expression; Purification

Mesh:

Substances:

Year:  2013        PMID: 23999711      PMCID: PMC3882918          DOI: 10.6091/ibj.1216.2013

Source DB:  PubMed          Journal:  Iran Biomed J        ISSN: 1028-852X


  21 in total

1.  Characterization and reconstitution of functional hemagglutinin of the Clostridium botulinum type C progenitor toxin.

Authors:  H Kouguchi; T Watanabe; Y Sagane; T Ohyama
Journal:  Eur J Biochem       Date:  2001-07

2.  Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.

Authors:  F Chen; G M Kuziemko; R C Stevens
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin.

Authors:  Jae-Chul Lee; Kenji Yokota; Hideyuki Arimitsu; Hyun-Jung Hwang; Yoshihiko Sakaguchi; Jinhua Cui; Kouichi Takeshi; Toshihiro Watanabe; Tohru Ohyama; Keiji Oguma
Journal:  Microbiology       Date:  2005-11       Impact factor: 2.777

4.  Role of nontoxic components of serotype D botulinum toxin complex in permeation through a Caco-2 cell monolayer, a model for intestinal epithelium.

Authors:  Koichi Niwa; Kumiko Koyama; Shin-Ichi Inoue; Tomonori Suzuki; Kimiko Hasegawa; Toshihiro Watanabe; Toshihiko Ikeda; Tohru Ohyama
Journal:  FEMS Immunol Med Microbiol       Date:  2007-04

5.  Four molecules of the 33 kDa haemagglutinin component of the Clostridium botulinum serotype C and D toxin complexes are required to aggregate erythrocytes.

Authors:  Shingo Mutoh; Tomonori Suzuki; Kimiko Hasegawa; Yozo Nakazawa; Hirokazu Kouguchi; Yoshimasa Sagane; Koichi Niwa; Toshihiro Watanabe; Tohru Ohyama
Journal:  Microbiology       Date:  2005-12       Impact factor: 2.777

Review 6.  Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.

Authors:  Zygmunt F Dembek; Leonard A Smith; Janice M Rusnak
Journal:  Disaster Med Public Health Prep       Date:  2007-11       Impact factor: 1.385

7.  Characterization of the genes encoding the botulinum neurotoxin complex in a strain of Clostridium botulinum producing type B and F neurotoxins.

Authors:  J A Santos-Buelga; M D Collins; A K East
Journal:  Curr Microbiol       Date:  1998-11       Impact factor: 2.188

8.  Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds.

Authors:  G Schiavo; A Santucci; B R Dasgupta; P P Mehta; J Jontes; F Benfenati; M C Wilson; C Montecucco
Journal:  FEBS Lett       Date:  1993-11-29       Impact factor: 4.124

9.  Tetanus and botulism neurotoxins: isolation and assay.

Authors:  G Schiavo; C Montecucco
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

10.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.

Authors:  Min Dong; David A Richards; Michael C Goodnough; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  J Cell Biol       Date:  2003-09-22       Impact factor: 10.539

View more
  6 in total

1.  Design, Expression and Purification of Strongyloides stercoralis IgG4 Immunoreactive Protein (NIE) in Escherichia coli.

Authors:  Katayoun Dastan; Mehdi Assmar; Nour Amirmozafari; Fariborz Mansour Ghanaei; Mirsasan Mirpour
Journal:  Iran J Parasitol       Date:  2020 Jul-Sep       Impact factor: 1.012

2.  Prediction of the Mannose-Binding Site in the Agaricus bisporus Mannose-Binding Protein.

Authors:  Wangsa Tirta Ismaya; Raymond Rubianto Tjandrawinata; Heni Rachmawati
Journal:  Protein J       Date:  2021-05-06       Impact factor: 2.371

3.  Investigating the Efficiency of Recombinant FliC-Loaded Bacillus subtilis Spores in Mice Immunization against Salmonella enterica Serovar Typhi.

Authors:  Nafiseh Ghorbani; Mehdi Assmar; Nour Amirmozafari; Khosrow Issazadeh
Journal:  Iran J Public Health       Date:  2021-07       Impact factor: 1.429

Review 4.  Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.

Authors:  Warner W Carr; Neal Jain; J Wesley Sublett
Journal:  Adv Ther       Date:  2021-09-13       Impact factor: 3.845

Review 5.  Major pathogenic Clostridia in human and progress toward the clostridial vaccines.

Authors:  Lida Abdolmohammadi Khiav; Azadeh Zahmatkesh
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

6.  In Silico Study to Develop a Lectin-Like Protein from Mushroom Agaricus bisporus for Pharmaceutical Application.

Authors:  Wangsa Tirta Ismaya; Sophi Damayanti; Caroline Wijaya; Raymond R Tjandrawinata; Debbie Sofie Retnoningrum; Heni Rachmawati
Journal:  Sci Pharm       Date:  2016-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.